Blinatumomab and oral TKIs for the treatment of Ph ALL

Bookmark and Share
Published: 8 Dec 2020
Views: 1162
Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA

Prof Geyer speaks to ecancer about an ongoing phase II study which has been presented at this year’s ASH virtual conference regarding blinatumomab and concurrent oral tyrosine kinase inhibitor therapy as consolidation and maintenance therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia following chemotherapy-sparing induction.

He says the ongoing D-ALBA study (GIMEMA LAL2116) is also investigating BLIN DAS consolidation following 12 weeks of induction (prednisone DAS followed by DAS), w/out protocol-specified maintenance, and has demonstrated preliminary evidence of efficacy. As such, he says this study is designed as a phase II study of BLIN as part of a chemotherapy sparing strategy in patients with Ph ALL (BLISSPHALL), introducing BLIN as early as 6 weeks into treatment for patients in morphologic CR, with the aim of enhancing early MRD negativity and suppressing resistant clones early in disease course.

Prof Geyer in the end, talks about how the future results from this trial (when obtained) can be beneficial for treating patients with this type of lymphoma.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.